Shielding means staying at home and limiting contact with members of the household. Research also calls into question on how effective it is in reducing the incidence of COVID-19.
Strict social distancing, or “shielding,” of patients with rheumatic diseases to prevent COVID-19 infection doesn’t reduce the incidence of infection and is associated with worse mental health, researchers reported.
“Shielding” is a strict form of social distancing that requires people to remain in their homes and have minimal contact with others, even members of their own household. The European League Against Rheumatism and the British Society of Rheumatology recommended shielding for patients taking immunosuppressive medications.
British researchers looked at the effects of shielding among 1,693 patients who agreed to fill out questionnaires. Half (50%) had rheumatoid arthritis; 16%, psoriatic arthritis, and 5%, ankylosing spondylitis.
When they compared the 61 patients in the group that contracted COVID-19 with the 1,632 patients who didn’t, they found that roughly the same percentage of the COVID-19 patients had shielded as those non-COVID-19 patients (24 of 61, or 40% vs. 768 of 1,632, or 47%), although the comparison did not meet the usual standard for statistical significance.
“Our study suggests that overall strict social isolation had little impact on the incidence of COVID-19 infection,” wrote Natasha Cleaton and her co-authors in the report published in the Annals of the Rheumatic Diseases.
Cleaton also looked at the mental and physical heath effects of shielding, comparing the 722 who shielded to the 823 who did not among the patients who didn’t contract COVID-19. They found the mental and physical health of shielding patients to be significantly lower than those who didn’t shield.
“Patients are likely to require increased mental and physical support as result of the COVID pandemic,” wrote Cleaton and her co-authors, adding that further study is needed on the efficacy and effects of shielding.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
2 Commerce Drive
Cranbury, NJ 08512